<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dcterms="http://purl.org/dc/terms/">
<rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/6844">
    <dcterms:title><![CDATA[<strong>Hyperthyroidism keeps immunoglobulin levels but reduces milk fat and CD11b/c+ cells on early lactation</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[TIROXINA]]></dcterms:subject>
    <dcterms:subject><![CDATA[LECHE HUMANA]]></dcterms:subject>
    <dcterms:subject><![CDATA[LACTANCIA MATERNA]]></dcterms:subject>
    <dcterms:subject><![CDATA[LEUCOCITOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[ANTICUERPOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[HIPERTIROIDISMO]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2024]]></dcterms:subject>
    <dcterms:abstract><![CDATA[Thyroid hormones influence mammary gland differentiation and lactation by binding to thyroid hormone receptors. Hyperthyroidism disrupts pregnancy and lactation, affecting offspring growth and milk production. Despite maternal milk is a vital source of bioactive compounds and nutrients for newborns, it is unclear whether hyperthyroidism alters its composition, mainly immune factors. Therefore, our work aimed to evaluate the influence of hyperthyroidism on milk quality and immunological parameters during early lactation. Twelve-weekold female Wistar rats received daily injections of 0,25 mg/kg T4 (HyperT, n = 20) or vehicle (control, n = 19) starting 8 days before mating and continuing throughout pregnancy. Rats were euthanized on day 2 of lactation for analyzing the impact of hyperthyroidism on mammary gland, serum and milk samples. HyperT pups exhibited reduced weight, length and head circumference with altered serum hormones, glucose and albumin levels. HyperT mammary gland analysis revealed structural changes, including decreased alveolar area, adipose tissue, increased connective tissue and reduced epithelial elongation, accompanied by decreased TR&beta;1 RNA expression. HyperT milk displayed lower caloric value and fat concentration. HyperT animals exhibited altered milk immune cell counts, displaying increased numbers of CD45+ and CD3+ cells and decreased CD11b/c+ cells without changes on milk and serum IgA, IgG and IgG2a levels. In summary, we have demonstrated that hyperthyroidism affects mammary gland morphology, disrupts pup development and alters biochemical and immunological parameters. Our findings highlight the impact of maternal hyperthyroidism on offspring early development and milk immune composition, underscoring the importance of thyroid function in maternal and neonatal immune health.]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>S&aacute;nchez, Mar&iacute;a Bel&eacute;n</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Michel Lara, Mar&iacute;a Cecilia</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Neira, Flavia Judith</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Rodr&iacute;guez-Camejo, Claudio</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>R&iacute;os, Juan Manuel</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Viruel, Luciana Bel&eacute;n</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Moreno-Sosa, Mar&iacute;a Tamara</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Pietrobon, Elisa Olivia</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Soaje, Marta</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Jahn, Graciela Alma</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Hern&aacute;ndez, Ana</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Valdez, Susana Ruth</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Mackern-Oberti, Juan Pablo</strong>]]></dcterms:creator>
    <dcterms:source><![CDATA[<span data-sheets-formula-bar-text-style="font-size:13px;color:#000000;font-weight:normal;text-decoration:none;font-family:'Arial';font-style:normal;text-decoration-skip-ink:none;">Molecular and Cellular Endocrinology, v. 594, 2024. -- e112370</span>]]></dcterms:source>
    <dcterms:publisher><![CDATA[Elsevier]]></dcterms:publisher>
    <dcterms:date><![CDATA[2024]]></dcterms:date>
    <dcterms:rights><![CDATA[<div class="element-text">
<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong>La legislaci&oacute;n uruguaya protege el derecho</strong>&nbsp;de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p><strong>ADVERTENCIA -</strong>&nbsp;La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>
</div>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:extent><![CDATA[13 p.]]></dcterms:extent>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[<span data-sheets-formula-bar-text-style="font-size:13px;color:#000000;font-weight:normal;text-decoration:none;font-family:'Arial';font-style:normal;text-decoration-skip-ink:none;">10.1016/j.mce.2024.112370</span>]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/6817">
    <dcterms:title><![CDATA[<strong>Immunization with a Mu-class glutathione transferase from Echinococcus granulosus induces efficient antibody responses and confers long-term protection against secondary cystic echinococcosis</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[ECHINOCOCCUS GRANULOSUS]]></dcterms:subject>
    <dcterms:subject><![CDATA[GLUTATION-S-TRANSFERASA]]></dcterms:subject>
    <dcterms:subject><![CDATA[VACUNAS]]></dcterms:subject>
    <dcterms:subject><![CDATA[ANTICUERPOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2024]]></dcterms:subject>
    <dcterms:abstract><![CDATA[Cystic echinococcosis, a zoonosis caused by cestodes belonging to the Echinococcus granulosus sensu lato (s.l.) genetic complex, affects humans and diverse livestock species. Although a veterinary vaccine exhibiting high levels of antibody-mediated protection has successfully reached the market, the large genetic diversity among parasite isolates and their particular host preferences, makes still necessary the search for novel vaccine candidates. Glutathione transferases (GSTs) constitute attractive targets for immunoprophylaxis due to their outstanding relevance in helminth detoxification processes, against both exogenous and endogenous stressors. Among the six GSTs known to be expressed in E. granulosus s.l., EgGST1 (Mu-class), EgGST2 (Sigma-class), and EgGST3 (a still non-classifiable isoenzyme), show the highest proteomic expression. Therefore, their recombinant forms -rEgGST1, rEgGST2 and rEgGST3- were herein analyzed regarding their potential to induce long-term antiparasite protection in mice. Only immunization with rEgGST1 induced long-lasting protection; and accordingly, rEgGST1-specific antibodies enhanced the parasite killing through both the classical activation of the host complement system and the antibody-dependent cellular cytotoxicity by macrophages. These results support further testing of rEgGST1 as a vaccine candidate in diverse hosts due to the broad expression of EgGST1 in different parasite stages and tissues.]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>Arbildi, Paula</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Muniz Lagos, Ana Clara</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Fern&aacute;ndez, Eugenia</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Giorgi, Rosina</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Wiater, Kai</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Mourglia Ettlin, Gustavo</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Fern&aacute;ndez, Ver&oacute;nica</strong>]]></dcterms:creator>
    <dcterms:source><![CDATA[Microbes and Infection v. 26, 2024. -- e105364]]></dcterms:source>
    <dcterms:publisher><![CDATA[Elsevier]]></dcterms:publisher>
    <dcterms:date><![CDATA[2024]]></dcterms:date>
    <dcterms:rights><![CDATA[<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong>La legislaci&oacute;n uruguaya protege el derecho</strong>&nbsp;de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p><strong>ADVERTENCIA -</strong>&nbsp;La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:extent><![CDATA[9 p.]]></dcterms:extent>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[10.1016/j.micinf.2024.105364]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/6609">
    <dcterms:title><![CDATA[<strong>Nanobody-Based blocking of binding ELISA for the detection of Anti-NS1 Zika-Virus-Specific antibodies in convalescent patients</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[SEROLOGIA]]></dcterms:subject>
    <dcterms:subject><![CDATA[FLAVIVIRIDAE]]></dcterms:subject>
    <dcterms:subject><![CDATA[INMUNOENSAYO]]></dcterms:subject>
    <dcterms:subject><![CDATA[ANTICUERPOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[ZIKA]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2023]]></dcterms:subject>
    <dcterms:abstract><![CDATA[Zika virus has spread around the world with rapid pace in the last five years. Although symptoms are typically mild and unspecific, Zika&rsquo;s major impact occurs during pregnancy, generating a congenital syndrome. Serology plays a key role in its diagnosis. However, its use is limited due to the uncertainty caused by the cross-reaction of antibodies elicited in response to other flavivirus infections when tested in direct immunoassays. Using a panel of previously generated anti-Zika non-structural protein 1 (NS1) nanobodies, a set was selected that only recognizes epitopes present in Zika and is immunogenic to humans. A proper arrangement of these nanobodies was made and conditions were optimized in order to develop a novel serology assay. This new ELISA relies on the inhibition of the binding of a set of selected nanobodies to Zika-immobilized NS1 when previously incubated with Zika convalescent sera. Using the developed blocking of binding assay, it was possible to discriminate between Zika-specific and cross-reactive antibodies in serum samples from infections with Zika and other flaviviruses]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<a href="https://export.cvuy.uy/cv/?2151545e1e2bcf5a1aed18f0fcbc86f8f572989a1ff4170a7081b84aaee68c3f0c594002567678df9a2ad53f09c41af0654f6be4d057bda841a03a8994b48e31" target="_blank"><strong>Delfin Riela, Triana</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a href="https://export.cvuy.uy/cvsni/?urlId=0714ab9cf73af9870ec8809b325b44115e7a8c32a7bffc5b0260762ba5347b07fa4dc1efff263fa6245889f68b031f22fc09f7dd37fb84c74004165d1dca6005&amp;convocatoria=21&amp;formato=html" target="_blank"><strong>Rossotti, Mart&iacute;n A.</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Mattiuzzo, Giada</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Echaides, C&eacute;sar</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a href="https://export.cvuy.uy/cv/?f843e2759f6ee96f8a16e51ceccfaeb41eb83154ba5da266ce35c9e64d7ad49b7ee8622e336b48ac9846dbe51b76b49fb1d2738fdaf473a4c75dea6e4f1afd20" target="_blank"><strong>Gonz&aacute;lez Sapienza, Gualberto</strong></a>]]></dcterms:creator>
    <dcterms:source><![CDATA[Tropical Medicine and Infectious Disease, v.8, n&deg; 1, 2023. -- e55]]></dcterms:source>
    <dcterms:publisher><![CDATA[MDPI]]></dcterms:publisher>
    <dcterms:date><![CDATA[2023]]></dcterms:date>
    <dcterms:rights><![CDATA[<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong>La legislaci&oacute;n uruguaya protege el derecho</strong>&nbsp;de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p><strong>ADVERTENCIA -</strong>&nbsp;La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:extent><![CDATA[10 p.]]></dcterms:extent>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[10.3390/tropicalmed8010055]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/6381">
    <dcterms:title><![CDATA[<strong>Polyreactive antibodies as potential humoral biomarkers of host resistance to cystic echinococcosis</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[BIOMARCADORES]]></dcterms:subject>
    <dcterms:subject><![CDATA[EQUINOCOCOSIS]]></dcterms:subject>
    <dcterms:subject><![CDATA[HIDATIDOSIS]]></dcterms:subject>
    <dcterms:subject><![CDATA[ECHINOCOCCUS GRANULOSUS]]></dcterms:subject>
    <dcterms:subject><![CDATA[ANTICUERPOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2021]]></dcterms:subject>
    <dcterms:abstract><![CDATA[<p>Polyreactive antibodies (pAb) bind to a broad range of unrelated structures, providing hosts with functional components able to rapidly recognize and protect against different pathogens. However, their roles against helminth parasites are still unexplored. Here, pAb profiles were analysed in cystic echinococcosis (CE), a zoonosis caused by the cestode Echinococcus granulosus sensu lato. Levels of anti-DNP (2,4-dinitrophenyl-hapten) antibodies were measured as a surrogate parameter of pAb in different biological settings. Firstly, levels of serum and peritoneal pAb were measured during early experimental secondary CE, using both high (Balb/c) and low (C57Bl/6) susceptible mouse strains. Serum pAb mostly differed in normal mice, being pAb levels of IgG subclasses with poor anti-parasite activities predominant in Balb/c animals.<br />Conversely, peritoneal pAb isotypes/subclasses with efficient anti-parasite activities predominated in normal and infected C57Bl/6 mice. Secondly, sera from potentially resistant patients, susceptible individuals and healthy donors were analysed, showing higher pAb levels of the IgA and IgG&mdash;particularly IgG1&mdash;isotypes in potentially resistant individuals compared to control groups. Finally, since remarkable differences were observed in pAb profiles according to the intrinsic host susceptibility to the infection, we proposed here that pAb might be considered as potential humoral biomarkers<br />for host resistance to CE.</p>]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>Garc&iacute;a Luna, Joaqu&iacute;n</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Magnone, Javier</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Miles, Sebasti&aacute;n</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>L&oacute;pez Santurio, Camila</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Dematteis, Sylvia</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Mourglia Ettlin, Gustavo</strong>]]></dcterms:creator>
    <dcterms:source><![CDATA[Parasite Immunology&nbsp;v. 43, n&deg;3, 2021. -- pp. 1-6. -- e12802]]></dcterms:source>
    <dcterms:publisher><![CDATA[Wiley]]></dcterms:publisher>
    <dcterms:date><![CDATA[2021]]></dcterms:date>
    <dcterms:rights><![CDATA[<p dir="ltr"><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p dir="ltr"><span>(Por favor lea este aviso antes de abrir los documentos u objetos)</span></p>
<p dir="ltr"><strong>La legislaci&oacute;n uruguaya protege el derechode autor</strong><span>&nbsp;sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</span></p>
<span id="docs-internal-guid-9d2103f7-7fff-c813-00c7-2528fd4891ff"><strong>ADVERTENCIA:</strong><span>&nbsp;La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</span></span>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[<span id="docs-internal-guid-f6781b37-7fff-23b6-f29f-7d2d19c9cc81"><span>10.1111/pim.12802 </span></span>]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/6050">
    <dcterms:title><![CDATA[<strong>Linking murine resistance to secondary cystic echinococcosis with antibody responses targeting Echinococcus granulosus tegumental antigens</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[ECHINOCOCCUS GRANULOSUS]]></dcterms:subject>
    <dcterms:subject><![CDATA[ANTICUERPOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[INMUNOINFORMATICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2020]]></dcterms:subject>
    <dcterms:abstract><![CDATA[Successful establishment of a parasite infection depends partially on the host intrinsic susceptibility to the pathogen. In cystic echinococcosis (CE), a zoonotic disease caused by the cestode parasite Echinococcus granulosus, the infection outcome in the murine model of secondary CE varies according to the mouse strain used. In this regard, intrinsic differences in susceptibility to the infection were previously reported for Balb/c and C57Bl/6 mice, being C57Bl/6 animals less permissive to secondary CE. Induction of parasite-specific antibodies has been suggested to play relevant roles in such susceptibility/resistance phenomena. Here, we report an in deep comparison of antibody responses induced in both mouse strains. Firstly, only C57Bl/6 mice were shown to induce specific-antibodies with efficient anti-parasite activities during early secondary CE. Then, through ImmunoTEM and Serological Proteome Analysis (SERPA), an evaluation of specific antibody responses targeting parasite tegumental antigens was performed. Both strategies showed that infected C57Bl/6 mice -unlike Balb/c animals- narrowed their IgG recognition repertoire against tegumental antigens, targeting fewer but potentially more relevant parasite components. In this sense, tegumental antigens recognition between Balb/c and C57Bl/6 mice, either by natural and/or induced antibodies, was analyzed through SERPA and MALDI-TOF/TOF studies. A total of 13 differentially recognized proteins (DRPs) uniquely targeted by antibodies from C57Bl/6 mice were successfully identified, wherein a subset of 7 DRPs were only recognized by infection-induced antibodies, suggesting their potential as natural protective antigens. In this regard, immunoinformatic analyses showed that such DRPs exhibited higher numbers of possible T cell epitopes towards the H-2-IAb haplotype, which is present in C57Bl/6 mice but absent in Balb/c animals. In summary, our results showed that the genetic predisposition to generate better T-dependent antibody responses against particular tegumental antigens might be a key factor influencing host susceptibility in the murine model of secondary CE.]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>Miles, Sebasti&aacute;n</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Magnone, Javier</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Cyrklaff, Marek</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Arbildi, Paula</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Frischknecht, Friedrich</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Dematteis, Sylvia</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Mourglia Ettlin, Gustavo</strong>]]></dcterms:creator>
    <dcterms:source><![CDATA[Inmunobiology 2020]]></dcterms:source>
    <dcterms:publisher><![CDATA[Elsevier]]></dcterms:publisher>
    <dcterms:date><![CDATA[2020]]></dcterms:date>
    <dcterms:rights><![CDATA[<strong>Informaci&oacute;n sobre Derechos de Autor</strong> (Por favor lea este aviso antes de abrir los documentos u objetos)<strong> La legislaci&oacute;n uruguaya protege el derecho de autor sobre toda creaci&oacute;n</strong> literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006) ADVERTENCIA - La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.]]></dcterms:rights>
    <dcterms:format><![CDATA[Pdf]]></dcterms:format>
    <dcterms:language><![CDATA[Inglés]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[DOI: 10.1016/j.imbio.2020.151916]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/5968">
    <dcterms:title><![CDATA[<strong>Development of a new promoter to avoid the silencing of genes in the production of recombinant antibodies in chinese hamster ovary cells</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[GENES]]></dcterms:subject>
    <dcterms:subject><![CDATA[CELULAS DE OVARIO]]></dcterms:subject>
    <dcterms:subject><![CDATA[ANTICUERPOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[HAMSTER CHINO]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2019]]></dcterms:subject>
    <dcterms:abstract><![CDATA[Background: The production of recombinant proteins in mammalian cell lines is one of the most important areas in biopharmaceutical industry. Viral transcriptional promoters are widely used to express recombinant proteins in mammalian cell lines. However, these promoters are susceptible to silencing, thus limiting protein productivity. Some CpG islands can avoid the silencing of housekeeping genes; for that reason, they have been used to increase the production of recombinant genes in cells of animal origin. In this study, we evaluated the CpG island of the promoter region of the &beta;-actin gene of Cricetulus griseous (Chinese hamster), associated to the Cytomegalovirus (CMV) promoter, to increase recombinant antibodies production in Chinese Hamster Ovary (CHO) cells. Results: We focused on the non-coding region of CpG island, which we called RegCG. RegCG behaved as a promoter, whose transcriptional activity was mainly commanded by the CAAT and CArG boxes of the proximal promoter. However, the transcription started mainly at the intronic region before the proximal transcription start site. While the CMV promoter was initially more powerful than RegCG, the latter promoter was more resistant to silencing than the CMV promoter in stable cell lines, and its activity was improved when combined with the CMV promoter. Thereby, the chimeric promoter was able to maintain the expression of recombinant antibodies in stable clones for 40&thinsp;days at an average level 4 times higher than the CMV promoter. Finally, the chimeric promoter showed compatibility with a genetic amplification system by induction with methotrexate in cells deficient in the dihydrofolate reductase gene. Conclusions: We have generated an efficient synthetic hybrid transcription promoter through the combination of RegCG with CMV, which, in stable cell lines, shows greater activity than when both promoters are used separately. Our chimeric promoter is compatible with a genetic amplification system in CHO DG44 cells and makes possible the generation of stable cell lines with high production of recombinant antibodies. We propose that this promoter can be a good alternative for the generation of clones expressing high amount of recombinant proteins, essential for industrial applications.]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>Zu&ntilde;iga, Roberto A.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Guti&eacute;rrez Gonz&aacute;lez, Mat&iacute;as</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Collazo, Norberto</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Sotelo, Pablo Hern&aacute;n</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Ribeiro, Carolina H.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Altamirano, Claudia</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Lorenzo, Carmen</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Aguill&oacute;n, Juan Carlos</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Molina, Carmen</strong>]]></dcterms:creator>
    <dcterms:source><![CDATA[Journal of Biological Engineering v. 13, no. 1, 2019. --p. 1-13.--e59]]></dcterms:source>
    <dcterms:publisher><![CDATA[BioMed Central Ltd]]></dcterms:publisher>
    <dcterms:date><![CDATA[2019]]></dcterms:date>
    <dcterms:rights><![CDATA[<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong> La legislaci&oacute;n uruguaya</strong> protege el derecho de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p><strong> ADVERTENCIA -</strong> La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>]]></dcterms:rights>
    <dcterms:format><![CDATA[Pdf]]></dcterms:format>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[DOI: 10.1186/s13036-019-0187-y]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/5656">
    <dcterms:title><![CDATA[<strong>Structure and specificity of several triclocarban-binding single domain camelid antibody fragments</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[AGENTES BACTERIOSTATICOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[ANTICUERPOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[TRICLOCARBAN]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2018]]></dcterms:subject>
    <dcterms:abstract><![CDATA[The variable VHH domains of camelid single chain antibodies have been useful in numerous biotechnology applications due to their simplicity, biophysical properties, and abilities to bind to their cognate antigens with high affinities and specificity. Their interactions with proteins have been well‐studied, but considerably less work has been done to characterize their ability to bind haptens. A high‐resolution structural study of three nanobodies (T4, T9, and T10) which have been shown to bind triclocarban (TCC, 3‐(4‐chlorophenyl)‐1‐(3,4‐dichlorophenyl)urea) with near‐nanomolar affinity shows that binding occurs in a tunnel largely formed by CDR1 rather than a surface or lateral binding mode seen in other nanobody‐hapten interactions. Additional significant interactions are formed with a non‐hypervariable loop, sometimes dubbed “CDR4”. A comparison of apo and holo forms of T9 and T10 shows that the binding site undergoes little conformational change upon binding of TCC. Structures of three nanobody‐TCC complexes demonstrated there was not a standard binding mode. T4 and T9 have a high degree of sequence identity and bind the hapten in a nearly identical manner, while the more divergent T10 binds TCC in a slightly displaced orientation with the urea moiety rotated approximately 180° along the long axis of the molecule. In addition to methotrexate, this is the second report of haptens binding in a tunnel formed by CDR1, suggesting that compounds with similar hydrophobicity and shape could be recognized by nanobodies in analogous fashion. Structure‐guided mutations failed to improve binding affinity for T4 and T9 underscoring the high degree of natural optimization.<br />
]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>Tabares da Rosa, Sof&iacute;a</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Wogulis, Linda A.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Wogulis, Mark D.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a title="Curriculum Vitae" href="https://exportcvuy.anii.org.uy/CvEstatico/?urlId=f843e2759f6ee96f8a16e51ceccfaeb41eb83154ba5da266ce35c9e64d7ad49b7ee8622e336b48ac9846dbe51b76b49fb1d2738fdaf473a4c75dea6e4f1afd20&amp;formato=pdf&amp;convocatoria=21" target="_self"><strong>Gonz&aacute;lez Sapienza, Gualberto.</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Wilson, David K.</strong>]]></dcterms:creator>
    <dcterms:source><![CDATA[Journal of Molecular Recognition 2018.--p. 1-9.--e2755]]></dcterms:source>
    <dcterms:publisher><![CDATA[Wiley]]></dcterms:publisher>
    <dcterms:date><![CDATA[2018]]></dcterms:date>
    <dcterms:rights><![CDATA[<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong>La legislaci&oacute;n uruguaya protege el derecho</strong> de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p><strong>ADVERTENCIA -</strong> La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[DOI: 10.1002/jmr.2755]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/5645">
    <dcterms:title><![CDATA[<strong>Ageing impairs parasite-specific antibody responses in cystic echinococcosis</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[PARASITOLOGIA]]></dcterms:subject>
    <dcterms:subject><![CDATA[QUISTE HIDATICO]]></dcterms:subject>
    <dcterms:subject><![CDATA[ANTICUERPOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2018]]></dcterms:subject>
    <dcterms:abstract><![CDATA[Humoral immunity wanes during healthy ageing, increasing susceptibility to infections in the elderly. In this sense, information about parasite infections and human immunosenescence is scarce. Cystic echinococcosis (CE) is an infectious disease caused by the larval stage of the cestode parasite Echinococcus granulosus, whose prevalence in humans shows an increase with host age. Susceptibility to human CE has been associated with humoral immunity to some extent; and therefore, we have here analyzed the influence of host age on the serological profile of young, middle-aged, and aged patients. Our results highlighted the detrimental influence of ageing on the intensity and quality of the anti-parasite antibody response. Remarkable differences in serological profiles between young and aged individuals were observed. In this sense, through Principal Components Analysis we identified aged patients as those exhibiting overall less intense antibody responses, mainly in isotypes/subclasses supposed to exert efficient anti-parasite activities (e.g. IgE and IgG1). Thus, these humoral defects could at least partially explain the reported increase in CE prevalence among older individuals, since a weaker immune response in the elderly might facilitate the establishment and maintenance of the parasite infection. Finally, a possible association between age-dependent susceptibility to CE and host immunosenescence is discussed.]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>Mourglia Ettlin, Gustavo Daniel.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Miles, S.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Hern&aacute;ndez, A.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a title="Curriculum Vitae" href="https://exportcvuy.anii.org.uy/CvEstatico/?urlId=086432105a0be10ef4e4e57df7e51e5a096203688a890b013ec9a12794f41c17f3cd780253064d2d2485395b80b566f9216f3b1d82011d108cd4ea1ac4e03220&amp;formato=pdf&amp;convocatoria=21" target="_self"><strong>Dematteis, Sylvia.</strong></a>]]></dcterms:creator>
    <dcterms:source><![CDATA[Parasite Immunology v. 40, no. 1, 2018. --4p.--e12505]]></dcterms:source>
    <dcterms:publisher><![CDATA[Wiley]]></dcterms:publisher>
    <dcterms:date><![CDATA[2018]]></dcterms:date>
    <dcterms:rights><![CDATA[<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong>La legislaci&oacute;n uruguaya protege el derecho</strong> de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p><strong>ADVERTENCIA -</strong> La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:language><![CDATA[ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[DOI: 10.1111/pim.12505]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/5560">
    <dcterms:title><![CDATA[<strong>Composici&oacute;n qu&iacute;mica de PMSG (Pregnant Mare Serum Gonadotropin) : inmunolog&iacute;a de PMSG</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[<strong>PMSG</strong>]]></dcterms:subject>
    <dcterms:subject><![CDATA[<strong>ECG</strong>]]></dcterms:subject>
    <dcterms:subject><![CDATA[<strong>GONADOTROPINAS</strong>]]></dcterms:subject>
    <dcterms:subject><![CDATA[<strong>CABALLOS</strong>]]></dcterms:subject>
    <dcterms:subject><![CDATA[<strong>COMPOSICI&Oacute;N QUIMICA</strong>]]></dcterms:subject>
    <dcterms:subject><![CDATA[<strong>AMINOACIDOS</strong>]]></dcterms:subject>
    <dcterms:subject><![CDATA[<strong>INMUNOLOGIA</strong>]]></dcterms:subject>
    <dcterms:subject><![CDATA[<strong>ANTICUERPOS</strong>]]></dcterms:subject>
    <dcterms:publisher><![CDATA[Biblioteca-FQ]]></dcterms:publisher>
    <dcterms:date><![CDATA[1993]]></dcterms:date>
    <dcterms:format><![CDATA[Papel]]></dcterms:format>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Bibliograf&iacute;a]]></dcterms:type>
    <dcterms:temporal><![CDATA[1984-1991]]></dcterms:temporal>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/4710">
    <dcterms:title><![CDATA[<strong>Linear and extended : a common polyglutamine conformation recognized by the three antibodies MW1, 1C2 and 3B5H10</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[PEPTIDOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[GLUTAMINA]]></dcterms:subject>
    <dcterms:subject><![CDATA[POLIGLUTAMINA]]></dcterms:subject>
    <dcterms:subject><![CDATA[ANTICUERPOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2013]]></dcterms:subject>
    <dcterms:abstract><![CDATA[A long-standing pathomechanistic model proposes that the polyglutamine (polyQ)-length-dependent toxicity threshold observed in all polyQ diseases is triggered by a conformational change within the monomer that occurs only above a certain polyQ length. If true, this yet undefined and elusive mutant-specific toxic conformation would constitute a direct therapeutic target. Three anti-polyQ antibodies&mdash;MW1, 1C2 and 3B5H10&mdash;have been extensively used to probe the conformation of polyQ. The crystal structure of the MW1 epitope reveals a linear, non-pathogenic polyQ. In contrast, although the detailed structure of its epitope is unknown, the 3B5H10 antibody is widely advertised and used as a conformational antibody that recognizes the toxic conformation of expanded polyQ. We solved the crystal structure of the 1C2 antigen-binding domain (1C2-Fab) and performed a direct comparison between the 1C2, MW1 and 3B5H10 structures. The MW1 and 1C2 antibodies have similar sequences and structures, consistent with their binding to short polyQ and their polyQ length-discrimination properties. Unexpectedly, the 3B5H10 antibody also shares striking features with MW1 and 1C2, which prompted us to revisit its binding properties. We show that the 3B5H10 epitope is actually a short, non-pathogenic polyQ. All three antibodies MW1, 1C2 and 3B5H10 interact similarly with polyQ of various lengths, and bind small polyQ epitopes in similar linear and extended conformations. Together with studies published during the recent years, our work argues against the hypothesis that a mutant-specific conformation in monomeric polyQ molecules is the toxic entity responsible for polyQ diseases.<br /><br />]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>Klein Fabrice, A. C.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Zeder Lutz, Gabrielle</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Cousido Siah, Alexandra</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Mitschler, Andre</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Katz, Aline</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Eberling, Pascal</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Mandel, Jean Louis</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Podjarny, Alberto</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Trottier, Yvon</strong>]]></dcterms:creator>
    <dcterms:source><![CDATA[Human Molecular Genetics v. 22, no. 20, 2013. -- p. 4215-4223<br />
]]></dcterms:source>
    <dcterms:publisher><![CDATA[Oxford Academic]]></dcterms:publisher>
    <dcterms:date><![CDATA[2013]]></dcterms:date>
    <dcterms:rights><![CDATA[<p style="margin-bottom: 0cm;"><strong>Informaci&oacute;n sobre Derechos de Autor</strong><br /><br />(Por favor lea este aviso antes de abrir los documentos u objetos)<br /><br /><strong>La legislaci&oacute;n uruguaya</strong> protege el derecho de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes<br /><br />(LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)<br /><br /><strong>ADVERTENCIA -</strong> La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[https://doi.org/10.1093/hmg/ddt273]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/4451">
    <dcterms:title><![CDATA[<strong>Obtenci&oacute;n de anticuerpos monoclonales frente al ant&iacute;geno hidat&iacute;dico y su caracterizaci&oacute;n</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[ANTICUERPOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[ANTICUERPOS MONOCLONALES]]></dcterms:subject>
    <dcterms:subject><![CDATA[HIDATIDOSIS]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[1987]]></dcterms:subject>
    <dcterms:creator><![CDATA[<strong>Mu&ntilde;oz, C.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a title="Curriculum Vitae" href="http://buscadores.anii.org.uy/buscador_sni/exportador/ExportarPdf?hash=9d36a9655c915bddd80b664491d73ec8" target="_blank"><strong>Nieto, A.</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Gay&aacute;, A.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Mazie, J.</strong>]]></dcterms:creator>
    <dcterms:source><![CDATA[Revista Ib&eacute;rica de Parasitolog&iacute;a. Sup., 1987. -- p. 229-237]]></dcterms:source>
    <dcterms:publisher><![CDATA[<span class="valor">Instituto Jos&eacute; de Acosta. Secciones de Hemintolog&iacute;a y Parasitolog&iacute;a. Universidad de Granad</span>a]]></dcterms:publisher>
    <dcterms:date><![CDATA[1987]]></dcterms:date>
    <dcterms:rights><![CDATA[<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong> La legislaci&oacute;n uruguaya protege el derecho</strong> de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p><strong>ADVERTENCIA -</strong> La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:language><![CDATA[Inglés]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[ISSN: 0034-9623.]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/4141">
    <dcterms:title><![CDATA[<p><strong>T&iacute;tulo y avidez de anticuerpos antigliadina en enfermos cel&iacute;acos (Ec)</strong></p>]]></dcterms:title>
    <dcterms:subject><![CDATA[ANTICUERPOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[ENFERMEDAD CEL&Iacute;ACA]]></dcterms:subject>
    <dcterms:subject><![CDATA[ANTICUERPOS ANTIGLIADINA]]></dcterms:subject>
    <dcterms:subject><![CDATA[ENFERMEDADES AUTOINMUNES]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[1989]]></dcterms:subject>
    <dcterms:abstract><![CDATA[<img src="data:image/png;base64,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" alt="" />]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>Molina, M.C.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a title="Curriculum vitae" href="http://buscadores.anii.org.uy/buscador_sni/exportador/ExportarPdf?hash=8b2cacb0aafc512133624fa7b9bf174c" target="_blank"><strong>Salinas, G.</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a title="Curriculum vitae" href="http://buscadores.anii.org.uy/buscador_sni/exportador/ExportarPdf?hash=9d36a9655c915bddd80b664491d73ec8" target="_blank"><strong>Nieto, Alberto</strong></a>]]></dcterms:creator>
    <dcterms:source><![CDATA[Inmunolog&iacute;a&nbsp; v. 8, no. 3, 1989. -- p. 102-106]]></dcterms:source>
    <dcterms:rights><![CDATA[<p class="western" lang="es-ES" align="left"><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p class="western" lang="es-ES">(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p class="western" lang="es-ES"><strong>La legislaci&oacute;n uruguaya</strong> protege el derecho de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes</p>
<p class="western" lang="es-ES">(LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p class="western" style="margin-bottom: 0cm;" lang="es-ES"><strong>ADVERTENCIA</strong> - La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:language><![CDATA[Espa&ntilde;ol]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[ISSN (digital) 0213-0626]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/4003">
    <dcterms:title><![CDATA[<strong>Natural and induced antibodies contribute to differentialsusceptibility to secondary cystic echinococcosis of Balb/c andC57Bl/6 mice</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[ECHINOCOCCUS GRANULOSUS]]></dcterms:subject>
    <dcterms:subject><![CDATA[INMUNOBIOLOGIA]]></dcterms:subject>
    <dcterms:subject><![CDATA[ANTICUERPOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2016]]></dcterms:subject>
    <dcterms:abstract><![CDATA[tAntibodies are key immune players in several helminth infections and animal models have been centralfor the identification of their mechanisms of protection. Murine secondary cystic echinococcosis is auseful model for studying Echinococcus granulosus immunobiology, being the immune profile mountedby the experimental host a determinant of parasite success or failure in infection establishment. In thepresent study, we analyzed infection outcome using Balb/c and C57Bl/6 mice strains, and compared theirantibody responses in terms of quality and intensity. Our results showed that Balb/c is a highly susceptiblestrain to secondary cystic echinococcosis, while C57Bl/6 mice are quite resistant. Moreover, significantdifferences between strains were observed in natural and induced antibodies recognizing E. granulosusantigens, both at the systemic and peritoneal levels. Natural cross-reacting IgM, IgG2b and IgG3 antibodieswere detected in sera from both strains but with different intensities, and &ndash; remarkably &ndash; natural IgG2bshowed to be an intrinsic correlate of protection in both mice strains. Interestingly, na&iuml;ve C57Bl/6 serumdisplayed a higher protoscolicidal activity, and heterologous &ndash; but not homologous &ndash; transference ofC57Bl/6 na&iuml;ve serum into Balb/c mice, significantly reduced their infection susceptibility. In the peritonealcavity, different levels of natural cross-reacting IgM and IgG3 antibodies were detected in both micestrains, while cross-reacting IgG2b was detected only in C57Bl/6 mice. On the other hand, infected micefrom both strains developed isotype-mixed antibody responses, with Balb/c mice biasing their responsetowards high avidity IgG1 and C57Bl/6 mice showing a predominance of mixed IgM/IgG2c/IgG2b/IgG3.In this regard, IgG1 levels showed to be a correlate of susceptibility in both mice strains. In conclusion,our results suggest that antibodies &ndash; either natural or induced &ndash; play a role in the susceptibility degreeto murine secondary cystic echinococcosis.]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>Mourglia Ettlin, Gustavo Daniel</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Cucher, Marcela</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Arbildi, Paula</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Rosenzvit, Mara</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a title="Curr&iacute;culum vitae" href="http://buscadores.anii.org.uy/buscador_sni/exportador/ExportarPdf?hash=3d2eba59d2d4c6ef6f52fa30f8fc1854" target="_blank"><strong>Dematteis, Sylvia</strong></a>]]></dcterms:creator>
    <dcterms:source><![CDATA[Immunobiology v. 221, 2016. -- p. 103-115]]></dcterms:source>
    <dcterms:publisher><![CDATA[Elsevier]]></dcterms:publisher>
    <dcterms:date><![CDATA[2016]]></dcterms:date>
    <dcterms:rights><![CDATA[<p align="LEFT"><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong>La legislaci&oacute;n uruguaya</strong> protege el derecho de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes</p>
<p>(LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p style="margin-bottom: 0cm;"><strong>ADVERTENCIA</strong> - La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[http://dx.doi.org/10.1016/j.imbio.2015.07.016]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/3948">
    <dcterms:title><![CDATA[<strong>A Model to explain the influence of maternal idiotypes or antiidiotypes on the selection of available repertoires</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[IDIOTIPO]]></dcterms:subject>
    <dcterms:subject><![CDATA[ANTI-IDIOTIPO]]></dcterms:subject>
    <dcterms:subject><![CDATA[ANTICUERPOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[1991]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:creator><![CDATA[<strong>Dewit, D.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Baz, A.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Demeur, C.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Ryelandt, M.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Urbain, J.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Vansanten, G.</strong>]]></dcterms:creator>
    <dcterms:source><![CDATA[Cellular Molecular Biology of the Maternal-Fetal Relationship v. 212, , 1991. -- p. 151-157]]></dcterms:source>
    <dcterms:date><![CDATA[1991]]></dcterms:date>
    <dcterms:rights><![CDATA[<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong> La legislaci&oacute;n uruguaya protege el derecho</strong> de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p><strong> ADVERTENCIA -</strong> La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Cap&iacute;tulo de libro]]></dcterms:type>
    <dcterms:identifier><![CDATA[ISSN 0768-3154]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/3773">
    <dcterms:title><![CDATA[<strong>Streamlined method for parallel identification of single domain antibodies to membrane receptors on whole cells</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[ANTICUERPOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[RECEPTOR DE LA CELULA]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2015]]></dcterms:subject>
    <dcterms:abstract><![CDATA[Background<br /><br />Owing to their minimal size, high production yield, versatility and robustness, the recombinant variable domains (nanobodies) of camelid single chain antibodies are valued affinity reagents for research, diagnostic, and therapeutic applications. While their preparation against purified antigens is straightforward, the generation of nanobodies to difficult targets such as multi-pass or complex membrane cell receptors remains challenging. Here we devised a platform for high throughput identification of nanobodies to cell receptor based on the use of a biotin handle.<br />Methods<br /><br />Using a biotin-acceptor peptide tag, the in vivo biotinylation of nanobodies in 96 well culture blocks was optimized allowing their parallel analysis by flow cytometry and ELISA, and their direct use for pull-down/MS target identification.<br />Results<br /><br />The potential of this strategy was demonstrated by the selection and characterization of panels of nanobodies to Mac-1 (CD11b/CD18), MHC II and the mouse Ly-5 leukocyte common antigen (CD45) receptors, from a VHH library obtained from a llama immunized with mouse bone marrow derived dendritic cells. By on and off switching of the addition of biotin, the method also allowed the epitope binning of the selected Nbs directly on cells.<br />Conclusions<br /><br />This strategy streamlines the selection of potent nanobodies to complex antigens, and the selected nanobodies constitute ready-to-use biotinylated reagents.<br />General significance<br /><br />This method will accelerate the discovery of nanobodies to cell membrane receptors which comprise the largest group of drug and analytical targets.<br /><br />]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>Rossotti, Mart&iacute;n</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Tabares, Sof&iacute;a</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Alfaya, Luc&iacute;a</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Leizagoyen, Carmen</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Moron, Gabriel</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a title="Curriculum Vitae" href="http://buscadores.anii.org.uy/buscador_sni/exportador/ExportarPdf?hash=7ee0def1187be47e0710e877d9768b5a" target="_blank"><strong>Gonz&aacute;lez-Sapienza, Gualberto G.</strong></a>]]></dcterms:creator>
    <dcterms:source><![CDATA[Biochimica et Biophysica Acta v. 1850, no. 7, 2015. -- p. 1397-1404]]></dcterms:source>
    <dcterms:publisher><![CDATA[Elsevier]]></dcterms:publisher>
    <dcterms:date><![CDATA[2015]]></dcterms:date>
    <dcterms:rights><![CDATA[<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong><br /> <br /> (Por favor lea este aviso antes de abrir los documentos u objetos)<br /> <br /> <strong>La legislaci&oacute;n uruguaya</strong> protege el derecho de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes<br /> <br /> (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)<br /> <br /> <strong>ADVERTENCIA -</strong> La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[doi:10.1016/j.bbagen.2015.03.009]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/3772">
    <dcterms:title><![CDATA[<strong>Method for Sorting and Pairwise Selection of Nanobodies for the Development of Highly Sensitive Sandwich Immunoassays</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[INMUNOLOGIA]]></dcterms:subject>
    <dcterms:subject><![CDATA[CLONACION]]></dcterms:subject>
    <dcterms:subject><![CDATA[ANTICUERPOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[HIDROLASAS]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2015]]></dcterms:subject>
    <dcterms:abstract><![CDATA[Single domain heavychain binders (nanobodies) obtained from camelid antibody libraries hold a great promise for immunoassay development. However, there is no simple method to select the most valuable nanobodies from the crowd of positive clones obtained after the initial screening. In this paper, we describe a novel nanobody-based platform that allows comparison of the reactivity of hundreds of clones with the labeled antigen, and identifies the best nanobody pairs for two-site immunoassay development. The output clones are biotinylated in vivo in 96-well culture blocks and then used to saturate the biotin binding capacity of avidin coated wells. This standardizes the amount of captured antibody allowing their sorting by ranking their reactivity with the labeled antigen. Using human soluble epoxide hydrolase (sEH) as a model antigen, we were able to classify 96 clones in four families and confirm this classification by sequencing. This provided a criterion to select a restricted panel of five capturing antibodies and to test each of them against the rest of the 96 clones. The method constitutes a powerful tool for epitope binning, and in our case allowed development of a sandwich ELISA for sEH with a detection limit of 63 pg/mL and four log dynamic range, which performed with excellent recovery in different tissue extracts. This strategy provides a systematic way to test nanobody pairwise combinations and would have a broad utility for the development of highly sensitive sandwich immunoassays.]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>Rossotti, Mart&iacute;n</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Pirez, Macarena</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a title="Curriculum Vitae" href="http://buscadores.anii.org.uy/buscador_sni/exportador/ExportarPdf?hash=67c04f6a200d5de027ddb6804d7bae5f" target="_blank"><strong>Gonz&aacute;lez Techera, Andr&eacute;s</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Cui, Yongliang</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Bever, C. S.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Morisseau, C.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Leizagoyen, Carmen</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Gee, Shirley</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Hammock, B. D</strong><br /><br />]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a title="Curriculum Vitae" href="http://buscadores.anii.org.uy/buscador_sni/exportador/ExportarPdf?hash=7ee0def1187be47e0710e877d9768b5a" target="_blank"><strong>Gonz&aacute;lez-Sapienza, Gualberto G.</strong></a>]]></dcterms:creator>
    <dcterms:source><![CDATA[Analytical Chemistry v. 87, no. 23, 2015. -- p. 11907-14]]></dcterms:source>
    <dcterms:publisher><![CDATA[American Chemical Society]]></dcterms:publisher>
    <dcterms:date><![CDATA[2015]]></dcterms:date>
    <dcterms:rights><![CDATA[<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong><br /> <br /> (Por favor lea este aviso antes de abrir los documentos u objetos)<br /> <br /> <strong>La legislaci&oacute;n uruguaya</strong> protege el derecho de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes<br /> <br /> (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)<br /> <br /> <strong>ADVERTENCIA -</strong> La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[DOI: 10.1021/acs.analchem.5b03561]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/3653">
    <dcterms:title><![CDATA[<strong> The perinatal presence of antigen (p-azophenylarsonate) or anti-u antibodies lead to the loss of the recurrent idiotype (CRIA) in A/J mice.</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[ANTIGENOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[ANTICUERPOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[1994]]></dcterms:subject>
    <dcterms:abstract><![CDATA[The immune response of A/J mice against p-azophenylarsonate (Ars)&mdash;keyhole limpet hemocyanln(KLH) is characterized by the dominance, late in primary and during the secondary, of a recurrent Idiotype called CRIA, encoded by a canonical combination of Ig gene segments. In this study, A/J mice were given Ars coupled to deaggregated human gamma globulins (dHGG) within 24 h after delivery. The offsprings from these mice were then exposed as adults to Ars&mdash;KLH. These animals developed an unusual immune response. The level of anti-Ars antibodies was nearly normal but a dramatic shift In repertoire was observed: the cross-reactive idiotype which is the hallmark of the anti-Ars response in A/J mice was completely absent. The idiotype could be recovered by injection of anti-idiotypic antibodies alone, with no need of llpopolysaccharlde coupling. Therefore the presence of antigen at birth can lead to a strong perturbation of idiotype selection. Similar results were obtained with neonatal treatment using antl-IgM antibodies. After recovery of suppression, A/J mice can mount an anti-arsonate response of normal level but devoid of the dominant idiotype.]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>Ryelandt, M</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>De Wit, D</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Baz, A</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Huetz, F</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Nisol, F</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Macedo, F</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Barcy, S</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong> Brait, M</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Leo, O</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Bazin, H</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Urbain, J</strong>]]></dcterms:creator>
    <dcterms:source><![CDATA[International Immunology v. 4, 1994. -- p. 645-652]]></dcterms:source>
    <dcterms:publisher><![CDATA[The Japanese Society for Immunology]]></dcterms:publisher>
    <dcterms:date><![CDATA[1994]]></dcterms:date>
    <dcterms:rights><![CDATA[<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong>La legislaci&oacute;n uruguaya</strong> protege el derecho de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes</p>
<p>(LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p><strong>ADVERTENCIA</strong> - La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[doi: 10.1093/intimm/7.4.645]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/3623">
    <dcterms:title><![CDATA[<strong>Use of specific antibody and circulating antigen serum levels in the hydatid immunodiagnosis of asymptomatic population.</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[ANTICUERPOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[ANTIGENO]]></dcterms:subject>
    <dcterms:subject><![CDATA[QUISTE HIDATICO]]></dcterms:subject>
    <dcterms:subject><![CDATA[INMUNODIAGNOSTICO]]></dcterms:subject>
    <dcterms:subject><![CDATA[HIDATIDOSIS]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[1994]]></dcterms:subject>
    <dcterms:abstract><![CDATA[Levels of specific antibodies (Ab) and circulating antigens (CAg) were tested by ELISA in sera from 115 surgically confirmed hydatid patients, 41 individuals exhibiting other parasitic and unrelated diseases and 69 healthy subjects. Addition of CAg data to Ab detection in this sera collection increased sensitivity from 85% (only Ab) to 89% (Ab + CAg). Combination of ultrasonography with Ab and CAg serology for diagnosis of asymptomatic population in endemic areas was analyzed. One field survey (163 persons) involved both blood extraction and ultrasonography to all the population. Three people exhibited cyst images and all of them were Ab positive, while 6 Ab and 1 CAg positive individuals exhibited no cyst image. Another survey (1620 persons) involved a selection of 85 subjects for serology according to ultrasound data and record of family hydatid history. Twelve per cent exhibited no hydatid image being serologically positive and 14% were serologically negative but exhibited cyst image. Ultrasonography and serology (Ab and CAg) should be used in combination to maximize the diagnostic yield in asymptomatic population.]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>Barbieri, Mariela</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Severi, Mar&iacute;a Ang&eacute;lica</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>P&iacute;rez, Maria Ines</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Battistoni, Julio</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a title="Curriculum" href="http://buscadores.anii.org.uy/buscador_sni/exportador/ExportarPdf?hash=9d36a9655c915bddd80b664491d73ec8"><strong>Nieto, Alberto</strong></a>]]></dcterms:creator>
    <dcterms:source><![CDATA[International Journal for Parasitology v. 24, no. 7, 1994. -- p. 937-942]]></dcterms:source>
    <dcterms:publisher><![CDATA[Elsevier]]></dcterms:publisher>
    <dcterms:date><![CDATA[1994]]></dcterms:date>
    <dcterms:rights><![CDATA[<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong>La legislaci&oacute;n uruguaya</strong> protege el derecho de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes</p>
<p>(LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p><strong>ADVERTENCIA</strong> - La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[doi:10.1016/0020-7519(94)90157-0]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/3542">
    <dcterms:title><![CDATA[<strong> Human isotype antibody responses to an Onchocerca volvulus glutathione S-transferase.</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[AGLUTINACION]]></dcterms:subject>
    <dcterms:subject><![CDATA[ANTICUERPOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[ISOTIPOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[ONCHOCERCA VOLVULUS]]></dcterms:subject>
    <dcterms:subject><![CDATA[GLUTATIONA S-TRANFERASA]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[1996]]></dcterms:subject>
    <dcterms:creator><![CDATA[<a title="Curriculum" href="http://buscadores.anii.org.uy/buscador_sni/exportador/ExportarPdf?hash=8b2cacb0aafc512133624fa7b9bf174c"><strong>Salinas, Gustavo</strong></a>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Sinha, K</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Cooper, J. P</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Whitworth, J</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Taylor, D</strong>]]></dcterms:creator>
    <dcterms:source><![CDATA[Parasite Immunology v. 18, no. 8, 1996. -- p. 377-386]]></dcterms:source>
    <dcterms:publisher><![CDATA[Wiley]]></dcterms:publisher>
    <dcterms:date><![CDATA[1996]]></dcterms:date>
    <dcterms:rights><![CDATA[<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong>La legislaci&oacute;n uruguaya</strong> protege el derecho de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes</p>
<p>(LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p><strong>ADVERTENCIA</strong> - La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[DOI: 10.1046/j.1365-3024.1996.d01-124.x]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/3505">
    <dcterms:title><![CDATA[<strong>Antibody response of Echinococcus granulosus infected mice : recognition of glucidic and peptidic epitopes and lack of avidity maturation.</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[ECHINOCOCCUS GRANULOSUS]]></dcterms:subject>
    <dcterms:subject><![CDATA[ANTICUERPOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[1996]]></dcterms:subject>
    <dcterms:abstract><![CDATA[. granulosus;secondary hydatidosis in mice;carbohydrate epitopes;antibody avidity The antibody response was followed weekly during 68 weeks in 17 Balb/c mice intraperitoneally (i.p.) infected with 2000 Echinococcus granulosus protoscoleces (PSC) and in three mice i.p. immunized with 2000 dead PSC. Antibodies against hydatid cyst fluid (HCFA) and its peptidic (periodate-resistant) and carbohydrate (periodate-sensitive) epitopes were titrated by ELISA. Avidity and the antigen recognition pattern of antibodies were also analysed during infection and immunization by ELISA and immunoblot, respectively. The antibody response of infected mice showed quantitative and qualitative variations during infection, since both titre as well as recognition of peptide and carbohydrate epitopes in HCFA depended on time post infection. No avidity maturation was evident during the course of infection. Sera from infected mice recognized the 38 kDa subunit of Ag5 but did not react with the 8 kDa subunit of AgB. On the contrary, the antibody response of immunized mice showed only one peak of antibodies that recognized both peptidic and carbohydrate epitopes of HCFA. In addition, sera from these mice recognized mainly 60 and 110 kDa bands. Our results suggest that: a) avidity and antigen recognition patterns of antibodies in mice treated with live PSC are different from those treated with dead PSC; b) antibodies against HCFA glucidic or peptidic epitopes appear at different times post infection.]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>Ferragut, Gabriela</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a title="Curriculum" href="http://buscadores.anii.org.uy/buscador_sni/exportador/ExportarPdf?hash=9d36a9655c915bddd80b664491d73ec8"><strong>Nieto, Alberto</strong></a>]]></dcterms:creator>
    <dcterms:source><![CDATA[Parasite Immunology v. 18, , 1996. -- p. 393-402]]></dcterms:source>
    <dcterms:publisher><![CDATA[Wiley]]></dcterms:publisher>
    <dcterms:date><![CDATA[1997]]></dcterms:date>
    <dcterms:rights><![CDATA[<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong>La legislaci&oacute;n uruguaya</strong> protege el derecho de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes</p>
<p>(LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p><strong>ADVERTENCIA</strong> - La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[DOI: 10.1046/j.1365-3024.1996.d01-125.x]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/3458">
    <dcterms:title><![CDATA[<strong>Chloroactivated latex particles for covalent coupling of antibodies. Application to immunoassays.</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[LATEX]]></dcterms:subject>
    <dcterms:subject><![CDATA[ANTICUERPOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[INMUNOENSAYOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[1997]]></dcterms:subject>
    <dcterms:abstract><![CDATA[The aim of the present work is to prepare and characterize a functionalized latex with chloromethyl groups on the surface and to perform the covalent coupling of anti-human serum albumin (a-HSA) IgG protein. The chloromethyl-styrene latex (CMS) was synthesized by means of a core-shell emulsion polymerization in a batch reactor. The monodisperse-obtained latex was characterized by determining the diameter (TEM and PCS), the surface charge density (conductometric and potentiometric titration), the amount of chloromethyl groups on the surface (hydrolysis reaction), and the stability vs electrolyte concentration (turbidity measurements). Electrokinetic characterization was also performed (electrophoretic mobility versus pH and ionic strength). IgG was chemically bound to the latex particles under different sensitization and block-stabilization conditions. Colloidal stability of complexes was studied to select an immunolatex suitable for the development of latex immunoassays. The final part of this work consists of a study of the immunoreactivity of the IgG-latex complexes at different pH and ionic strength, in particular under physiological conditions. The results show that chemically bound IgG to chloromethyl latex provides an IgG-latex complex suitable for application in immunodiagnosis tests.]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>Miraballes, I</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Mart&iacute;n, A</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong> Hidalgo, R</strong>]]></dcterms:creator>
    <dcterms:source><![CDATA[Journal of Biomaterials Science, Polymer edition v. 8, 1997. -- p. 765-777]]></dcterms:source>
    <dcterms:publisher><![CDATA[Taylor and Francis]]></dcterms:publisher>
    <dcterms:date><![CDATA[1997]]></dcterms:date>
    <dcterms:rights><![CDATA[<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong>La legislaci&oacute;n uruguaya</strong> protege el derecho de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes</p>
<p>(LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p><strong>ADVERTENCIA</strong> - La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[DOI: 10.1163/156856297X00308]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/3447">
    <dcterms:title><![CDATA[<strong>Analysis of cytokine and specific antibody profile in hydatid patients with primary infection and relapse of diseas.</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[CITOCINAS]]></dcterms:subject>
    <dcterms:subject><![CDATA[ANTICUERPOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[HIDATIDOSIS]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[1997]]></dcterms:subject>
    <dcterms:abstract><![CDATA[We studied in vitro cytokine production by peripheral blood mononuclear cells (PBMC) from patients with primary and recurrent hydatid disease when cells were incubated with mitogen (PHA) and antigen from hydatid cyst fluid (HCFAg); levels of specific IgE, IgG4 and eosinophil counts were also measured in sera. When specifically stimulated, PBMC from patients produced higher levels of IL-2 (P &lt; 0&middot;02), IFN- g (P &lt; 0&middot;0028) and IL-5 (P &lt; 0&middot;01) than those from uninfected donors, whereas IL-10 levels were comparable. Notably, IL-5 was also produced in higher levels (P &lt; 0&middot;01) by PBMC from patients when incubated with PHA. The IL-5:IFN- g ratio was significantly greater (P &lt; 0&middot;02) when measured in response to specific stimulation than it was for PHA-stimulated cultures. These cytokine data suggest a bias towards a Th2-response which is in agreement with the high levels of IgG4 and IgE observed. The polarized response appears to be related to clinical status, as differences between patients with primary infec- tion and those with relapse of disease were demonstrated, with significantly higher levels of IgE (P &lt; 0&middot;003), IgG4 (P &lt; 0&middot;04) titres and eosinophil counts (P &lt; 0&middot;04) in the latter; in addition a tendency to an increased production of IL-5 buy lower IFN- g was also observed in this group. These results merit further study as they are suggestive of a putative role of Th2-like responses in susceptibility to reinfection by E. granulosus]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>Hern&aacute;ndez, A</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Borras, R</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong> Mir, G</strong>]]></dcterms:creator>
    <dcterms:source><![CDATA[Parasite Immunology, vol 19, 1997. -- p. 553-561]]></dcterms:source>
    <dcterms:publisher><![CDATA[Blackwell]]></dcterms:publisher>
    <dcterms:date><![CDATA[1997]]></dcterms:date>
    <dcterms:rights><![CDATA[<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong>La legislaci&oacute;n uruguaya</strong> protege el derecho de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes</p>
<p>(LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p><strong>ADVERTENCIA</strong> - La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[DOI: 10.1046/j.1365-3024.1997.d01-173.x]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/3410">
    <dcterms:title><![CDATA[<strong>Evolution of IgG antibody response against T.gondii tissue cyst in acute and chronic human infections.</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[TRYPANOSOMA GONDII]]></dcterms:subject>
    <dcterms:subject><![CDATA[INMUNOGLOBULINA - IgG]]></dcterms:subject>
    <dcterms:subject><![CDATA[ANTICUERPOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[1998]]></dcterms:subject>
    <dcterms:abstract><![CDATA[The recognition profile of the tissue cysts antigens by IgG antibodies was studied during acute and chronic human toxoplasmic infection. Thus the IgG response against Toxoplasma gondii was investigated by immunoblotting in two patients accidentally infected with the RH strain as well as in group of naturally infected patients at acute and chronic phase. There was an overall coincidence of molecular mass among antigens of tachyzoites and tissue cysts recognized by these sera, however, they appear not to be the same molecules. The response against tissue cysts starts early during acute infection, and the reactivity of antibodies is strong against a wide range of antigens. Six bands (between 82 and 151 kDa) were exclusively recognized by chronic phase sera but only the 132 kDa band was positive in more than 50% of the sera analysed. A mixture of these antigens could be used to discriminate between the two infection phases. The most important antigens recognized by the acute and the chronic phase sera were 4 clusters in the ranges 20-24 kDa, 34-39 kDa, 58-80 kDa and 105-130 kDa as well as two additional antigens of 18 and 29 kDa. Both accidentally infected patients and some of the naturally infected patients showed a weak specific response against tissue cyst antigens.]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>Villavedra, M</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Carol, H</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a title="Curriculum" href="http://buscadores.anii.org.uy/buscador_sni/exportador/ExportarPdf?hash=9d36a9655c915bddd80b664491d73ec8"><strong>Nieto, Alberto</strong></a>]]></dcterms:creator>
    <dcterms:source><![CDATA[Revista do Instituto de Medicina Tropical de Sao Paulo v. 40, no. 2, 1998. -- p. 77-84]]></dcterms:source>
    <dcterms:publisher><![CDATA[Instituto de Medicina Tropical]]></dcterms:publisher>
    <dcterms:date><![CDATA[1998]]></dcterms:date>
    <dcterms:rights><![CDATA[<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong>La legislaci&oacute;n uruguaya</strong> protege el derecho de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes</p>
<p>(LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<strong>ADVERTENCIA</strong> - La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[ISSN 0036-4665]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/3382">
    <dcterms:title><![CDATA[<strong>Preparation of reagents from blood group serology : illustrating basic concepts of the antibody respons.</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[SEROLOGIA]]></dcterms:subject>
    <dcterms:subject><![CDATA[ANTICUERPOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[URUGUAY]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[1998]]></dcterms:subject>
    <dcterms:abstract><![CDATA[The aim of the present work is to illustrate basic issues relating to the antibody response through the preparation reagents for blood group serology. Two rabbits were immunised with the stromata of A and B cells. The antibody response was analysed by ELISA and Haemagglutination. The appropriate bleeding was selected in order to prepare the reagents. They were tested by blood grouping a panel of volunteers and comparing the results with those obtained with a commercial kit.]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>Miguez, M</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Marco, M</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Caceres, S</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a title="Curriculum" href="http://buscadores.anii.org.uy/buscador_sni/exportador/ExportarPdf?hash=9d36a9655c915bddd80b664491d73ec8"><strong>Nieto, Alberto</strong></a>]]></dcterms:creator>
    <dcterms:source><![CDATA[Biochemical Education v. 26, , 1998. -- p. 168-172]]></dcterms:source>
    <dcterms:publisher><![CDATA[Elsevier]]></dcterms:publisher>
    <dcterms:date><![CDATA[1998]]></dcterms:date>
    <dcterms:rights><![CDATA[<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong>La legislaci&oacute;n uruguaya</strong> protege el derecho de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes</p>
<p>(LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p><strong>ADVERTENCIA</strong> - La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:coverage><![CDATA[Uruguay]]></dcterms:coverage>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/3322">
    <dcterms:title><![CDATA[<strong>Characterization of MARCKS (Myristoylated Alanine-Rich C Kinase Substrate) identified by a monoclonal antibody generated against chick embryo neural retina.</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[BIOLOGIA MOLECULAR]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIOLOGIA CELULAR]]></dcterms:subject>
    <dcterms:subject><![CDATA[PROTEINAS]]></dcterms:subject>
    <dcterms:subject><![CDATA[ANTICUERPOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[1999]]></dcterms:subject>
    <dcterms:abstract><![CDATA[To identify molecular markers of cell differentiation in developing nervous tissue, monoclonal antibodies against chick embryo neural retina were made. One of them, 3C3mAb, recognized a developmentally regulated antigen present in several organs of the CNS. Data from MALDI-TOF mass spectrometry and peptide sequencing of the immuno-affinity purified protein indicated identity of the antigen with MARCKS. The immunoreactive material was always found as a unique polypeptide (Mr 71 kDa) in SDS-PAGE, however isoelectrofocusing revealed the existence of several bands (pI ranging from 4.0 to 4.5). Interestingly some retinal cell types, as photoreceptors, exhibited an extremely significant decrease in the intensity of the immunoreactive material during the final phases of terminal differentiation while others, as some retinal neurons, maintained the immunoreactivity when fully differentiated. Taken together these results indicate that MARCKS, a protein susceptible of several posttranslational modifications as myristoylation and phosphorylation at variable extent, may act differently in neural retina cell types.]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>Zolessi Elizalde, Flavio Rafael</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Hellman, Ulf</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Baz Morelli, Adriana</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Arruti, C</strong>]]></dcterms:creator>
    <dcterms:source><![CDATA[Biochemical and Biophysical Research Communications v.257, 1999. -- p. 480-487]]></dcterms:source>
    <dcterms:publisher><![CDATA[Elsevier]]></dcterms:publisher>
    <dcterms:date><![CDATA[1999]]></dcterms:date>
    <dcterms:rights><![CDATA[<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong>La legislaci&oacute;n uruguaya</strong> protege el derecho de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes</p>
<p>(LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p><strong>ADVERTENCIA</strong> - La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[DOI: 10.1006/bbrc.1999.0490]]></dcterms:identifier>
</rdf:Description></rdf:RDF>
